• pic 1

    A medical device holding company

  • pic 2

    Development and acquisition of medical device businesses

  • pic 3

    Get in touch, send us an email

We specialise in interventional cardiology, radiology, peripheral vascular and non-vascular markets

PRESS RELEASE Q3 Medical Devices Ltd. and the Boill Group Continue Expansion Plans in China.  READ MORE

About us

Q3 Medical Devices Limited

Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The holding and its companies are focused on the development, manufacturing, and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors, and investors focused on the development and acquisition of medical device businesses with annual revenues between 1 -10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, growth of its distribution channels, and accelerating its products offering focused on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

Business Concept

Opportunity to expand

In a market where there has been considerable effort to increase the size and scope of the offerings across multiple specialties and where there has been significant consolidation at the Large Cap and Mid Cap Level Q3 Medical believes there is a significant opportunity to expand its competitive base through the organic growth of its existing businesses and through acquisitions.

Our vision

Q3 Medical is focused on opportunities that will accelerate the expansion of its core manufacturing base as well as enhanced capabilities for innovative developments, distribution channel expansion, and accelerated product offering for patients with cardiology, peripheral vascular and non-vascular diseases.

Strategy

Q3 Medical believes that the global market is dependent on 3 main drivers for strategic success:
1. Developing innovative solutions that can drive cost from the healthcare system while increasing capacity while providing a high quality product at a reasonable price.
2. Relationship with the triangle if influence (Finance, Care Givers, and Patients) play an ever increasing role in success.
3. Consolidation creates opportunities for the company’s core business expansion in production, development, and distribution.

Q3 Medical plans to leverage its capabilities in innovation, channel management, and acquisition to insure its long term success.

News

Q3 Medical Devices Ltd. and the Boill Group Continue Expansion Plans in China

Q3 Medical Devices Ltd. Meets with Baoshan Local Government to Promote Future High-Tech Medical Device Manufacturing Facility


Shanghai – April 2018 – Q3 Medical Devices Ltd (Q3) and the Boill Holding Group, met with high ranking officials from the local government in the Baoshan region of China, to discuss and promote their investment into high tech medical device manufacturing infrastructure of the region.

“We are incredibly excited to be able to bring a high-tech manufacturing facility to the Baoshan region of China,” said Eric K. Mangiardi, Chairman & CEO of Q3 Medical. He continued to state, “by leveraging the medical device manufacturing knowledge and experience of Q3 and its subsidiaries along with the resources and investment from the Boill Holding Group, we will be able to deliver on our promise of better patient care by developing and manufacturing innovative technology with high quality German manufacturing standards.”


(Photo 1) District Mayor Fan Shao Jun of the Baoshan local government (right) greets Eric K. Mangiardi, CEO of Q3 Medical Devices Limited (left) to discuss the future high-tech medical device manufacturing facility.

(Photo 2) Ongoing construction of the new high-tech medical device manufacturing and R&D facility in the Baoshan region)

Q3 with over 150 global staff and 4 wholly owned subsidiaries in various growth stages based in the United States (Qualimed, USA), Germany (QualiMed and AMG), and China (Q-San) are focused on the development, registration, manufacturing, and commercialization of its innovations. The wholly owned subsidiaries are focused on the global expansion of its novel bioresorbable, micro invasive, drug delivery, and core products platforms for interventional cardiology, peripheral vascular, and non-vascular diseases.

Boill Chairman, Qiu Dong Fang remarked, “we are very excited to be the leading investor in Q3 and to have them in the Boill E Wisdom Valley Industrial Park to help transform the local manufacturing community into a high-tech medical device center of excellence. To be able to manufacture such advanced technology at our park will insure the future success of our transformation project focused on Comprehensive Healthcare and helping to turn the center into a best in class manufacturing site. Having products that can have such a positive clinical impact and benefit to local patients and those throughout China will be a source of great pride for all of us.”

With the new high-tech manufacturing facility set to open within the next year, District Mayor Fan Shao Jun of the Baoshan local government stated, “we are very happy to have such a high-tech and innovative medical device R&D and manufacturing enterprise come to Baoshan and contribute to our ongoing transformation to a high-tech manufacturing and R&D agglomeration. With their innovative bioresorbable technology that allows patients to potentially forgo a secondary procedure and its micro invasive products focused on reducing potential complications, we expect the company to deliver healthcare benefits to the patients in the greater Baoshan District, the Shanghai region, greater China, and the world.”

If you would like more information, please contact Eric K. Mangiardi at emangiardi@q3medical.com.


About Q3 Medical Devices Ltd.
Q3 Medical Devices Ltd. is an Ireland based holding company with multiple global operations in Germany, China, & the United States along with a strong global partnerships, and an ever growing strategic investor base, including China Pioneer Pharma Holdings Limited listed on the Hong Kong Exchange (1345) and Boill Holding Group, Shanghai China. The holding and its companies are focused on the development, manufacturing and distribution of its novel bioresorbable, micro invasive, drug delivery, and core products platforms for interventional cardiology, peripheral vascular, and non-vascular diseases.

Q3 Medical Devices Ltd. was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors and investors, focused on the development and acquisition of medical device businesses with annual revenues between 1-10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities, grow its distribution channel and accelerate its products offering, focusing on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

For further information, visit http://www.q3medical.com/.


About Boill Holding Group
Boill Holding Group is an international diversified investment group with a global presence focused on real estate development, and transformational investments in the emerging industries of comprehensive healthcare and intelligent manufacturing sectors. With over 12 Billion RMB in Assets Boill will continue to focus on expanding its global presence in the Asset Management and Financial Investment areas with focus on the comprehensive healthcare and intelligent manufacturing sectors.

Founded in 1996 and headquartered in Shanghai, China Boill Holding Group, though the visionary leadership of Chairman Qiu Dong Fang has lead the transformation from a traditional real estate development enterprise to a diversified conglomerate with a global presence in Hong Kong, Japan, Australia, France, Ireland, and the USA.

For more information, visit http://www.boill.com/. 


Forward Looking Statements
This announcement includes “forward-looking statements” which incorporate all statements other than statements of historical facts, including, without limitation, those regarding the Group’s financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group’s products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words “targets”, “believes”, “estimates”, “expects”, “aims”, “intends”, “will”, “can”, “may”, “anticipates”, “would”, “should”, “could” or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group’s control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group´s present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group’s actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Q3 Medical’s & QualiMed’s funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements are valid at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

Opportunity

Competitive Opportunity

Q3 Medical believes it has a competitive advantage through its owned companies through the:
1. Introduction of a wide ranging technology platform with enhanced capabilities across the large clinical market in the 20 Billion + market for interventional Cardiology, Radiology/Peripheral Vascular, and Non Vascular products.
2. Versatility and innovation in its manufacturing base to develop technology that can reduce cost of care.
3. Leveraging of its global relationships and those of its current and future channel partners who have been left with limited product choice opportunities due channel consolidations resulting from large cap and mid cap channel acquisitions.

Growth Targets

The company expects to see organic grow through the introduction of new technology offering of its owned companies and through acquisitions that will accelerate its growth focused on expanding its core manufacturing base as well as enhanced capabilities for innovative developments, distribution channel expansion, and accelerated product offering for the minimally invasive treatment of patients with cardiology, peripheral vascular, and non-vascular diseases.

Organization

Q3 Medical Devices Limited is a holding business organized to assist its companies in the management and facilitation of:
1. Capital needs and risk
2. Improved efficiencies
3. Accelerated growth

Q3 Medicals organization is organized to react rapidly to market changes made, facilitated, and implemented at the business level while matters of acquisition strategy, areas of future focus, and strategic direction are made at the Q3 board level. Each business is independently responsible for its operations including but not limited to product development, production, and distribution.

Areas

Interventional Cardiology

  • Interventional cardiology is a branch of cardiology that deals specifically with the catheter based treatment of structural heart diseases. The main advantages of using the interventional cardiology or radiology approach are the avoidance of the scars and pain, and long post-operative recovery.

    Additionally, interventional cardiology procedure of primary angioplasty is now the gold standard of care for an acute myocardial infarction. It involves the extraction of clots from occluded coronary arteries and deployment of stents and balloons through a small hole made in a major artery, which has given it the name "pin-hole surgery" (as opposed to "key-hole surgery").

Intervention Radiology / Peripheral Vascular

  • Interventional radiology is a medical sub-specialty of radiology which utilizes minimally-invasive image-guided procedures to diagnose and treat diseases in nearly every organ system. The concept behind interventional radiology is to diagnose and treat patients using the least invasive techniques currently available in order to minimize risk to the patient and improve health outcomes.

    As the inventors of angioplasty and the catheter-delivered stent, interventional radiologists pioneered modern minimally-invasive medicine. Using X-rays, CT, ultrasound, MRI, and other imaging modalities, interventional radiologists obtain images which are then used to direct interventional instruments throughout the body. These procedures are usually performed using needles and narrow tubes called catheters, rather than by making large incisions into the body as in traditional surgery.

Interventional Non Vascular

  • Non-vascular interventions are minimally invasive interventional radiology procedures that do not involve blood vessels. The physician uses imaging technology to guide instruments inside the body without open surgery.

    Interventional radiologists often use ultrasound and CT scans to guide catheter (tube) placement to drain abscesses and other fluid collections. Imaging technology is also used for biopsies of deep tumors in the chest, abdomen and pelvis.

Meet the group

Eric K Mangiardi
C.E.O.

Prior to this role, Mangiardi held Board positions and or was an investor in QualiMed , AMG, and Alveolus where he served as the CEO and founder before the company was acquired by Merit Medical and now forms that foundation of their Merit Endotek Division. He has 20 years of experience and a number of patents and patent applications in his name for various novel medical devices. Mangiardi holds an MSc in International Marketing, from the University of Strathclyde, Glasgow, Scotland and a Bachelors of Science in Finance and Marketing from the University of Dayton, USA.


Manfred Gülcher
Chief Risk Officer

Prior to this role, Gülcher was Founder and Co-Managing Director at QualiMed where he held numerous position as the Head of Regulatory, Quality, Drug Device Combination Technologies, and oversaw the legal functions within the business. Gülcher is a graduate in Electronic Engineering and previously worked as manager for quality and regulatory affairs at Devon Medical GmbH, Hamburg, and as Head of medical devices approval at DEKRA GmbH.

Group of companies


qualimed

As a leader in the development of innovative medical device technology to a large variety of interventional and surgical specialties doctors and the patients they treat globally, QualiMed is continually focused on enhancing its team of medical device professionals who are interested in working in the fast paced ever changing environment of medical device development.

Qualimed Innovative Medizinprodukte GmbH
Boschstrasse 16, 21423, Winsen, Germany

Phone +49 4171 6578 0
Fax +49 4171 6578 11
info@qualimed.de
www.qualimed.de

qualimed

amg International develops, manufactures and sells stents, stent implantation systems and balloon catheters, which are used primarily in interventional cardiology. That is why we call ourselves – Das Stent Company. amg International aims to provide the cardiologist with a continuous flow of innovative new products.

amg International GmbH
Boschstrasse 16, 21423, Winsen, Germany

Phone +49 4171 69 05 57 0
Fax +49 4171 69 05 57 11
info@thestentcompany.com
www.thestentcompany.com

altea world map

Contact us

Security

Address:
Q3 Medical Devices Limited
88 Harcourt Street
Dublin 2, Ireland

 +49 172 243 9649
 info@q3medical.com

DISCLAIMER Copyright © 2013. Q3 Medical Devices Limited.
Powered by Pre Inception